BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/21/2025 10:13:03 AM | Browse: 110 | Download: 494
 |
Received |
|
2024-11-06 12:30 |
|
Peer-Review Started |
|
2024-11-06 12:31 |
|
First Decision by Editorial Office Director |
|
2024-12-24 03:32 |
|
Return for Revision |
|
2024-12-24 03:32 |
|
Revised |
|
2025-01-05 20:35 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-01-13 02:39 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-01-14 13:12 |
|
Articles in Press |
|
2025-01-14 13:12 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-01-20 03:06 |
|
Publish the Manuscript Online |
|
2025-02-21 10:13 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Editorial |
| Article Title |
Personalized translational medicine: Investigating YKL-40 as early biomarker for clinical risk stratification in hepatocellular carcinoma recurrence post-liver transplantation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ileana Lulic, Dinka Lulic, Jadranka Pavicic Saric, Iva Bacak Kocman and Dunja Rogic |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ileana Lulic, MD, Postdoctoral Fellow, Department of Anesthesiology, Intensive Care and Pain Medicine, Clinical Hospital Merkur, Zajceva 19, Zagreb 10000, Croatia. ileanalulic@gmail.com |
| Key Words |
Hepatocellular carcinoma recurrence; Liver transplantation; Personalized translational medicine; Biomarkers; YKL-40; Risk stratification |
| Core Tip |
YKL-40 aligns with the principles of personalized translational medicine by offering a biomarker-driven approach to patient care. Its ability to provide liver-specific insights enables tailored post-liver transplantation surveillance and risk stratification, addressing the unique recurrence risks of individual patients. By integrating YKL-40 into multi-biomarker panels and predictive models, clinicians can refine therapeutic strategies, monitor disease progression more effectively, and personalize interventions for high-risk individuals. This targeted approach not only enhances clinical outcomes but also supports the broader shift toward precision medicine in transplantation, ensuring that care is both patient-specific and evidence-driven. |
| Publish Date |
2025-02-21 10:13 |
| Citation |
Lulic I, Lulic D, Pavicic Saric J, Bacak Kocman I, Rogic D. Personalized translational medicine: Investigating YKL-40 as early biomarker for clinical risk stratification in hepatocellular carcinoma recurrence post-liver transplantation. World J Transplant 2025; 15(2): 103036
|
| URL |
https://www.wjgnet.com/2220-3230/full/v15/i2/103036.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v15.i2.103036 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
